<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Public expenditure on health and social care</title></head><body><div><p style="margin:0pt; text-align:right"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 13.05pt 0pt 0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Written evi</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">dence from</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold"> Roche Diagnostics </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">UK (PEX 0011)</span></p><p style="margin:0pt 13.05pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 13.05pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Summary</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; margin:5pt 13.05pt 0pt 32pt; padding-left:4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">The </span><span style="font-family:'Times New Roman'; font-size:12pt">‘</span><span style="font-family:'Times New Roman'; font-size:12pt">Nicholson Challenge</span><span style="font-family:'Times New Roman'; font-size:12pt">’</span><span style="font-family:'Times New Roman'; font-size:12pt"> set ambitious targets for </span><span style="font-family:'Times New Roman'; font-size:12pt">achieving</span><span style="font-family:'Times New Roman'; font-size:12pt"> £20 billion efficiency savings in the NHS. However, there is increasing evidence that cuts rather than efficiencies are being made </span><span style="font-family:'Times New Roman'; font-size:12pt">to</span><span style="font-family:'Times New Roman'; font-size:12pt"> services for people with long-term conditions, which account for a significant proportion of NHS expenditure.</span></li></ol><p style="margin:0pt 13.05pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; margin:0pt 13.05pt 0pt 32pt; padding-left:4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">I</span><span style="font-family:'Times New Roman'; font-size:12pt">nitiatives to tackle increasing </span><span style="font-family:'Times New Roman'; font-size:12pt">NHS </span><span style="font-family:'Times New Roman'; font-size:12pt">expenditure, </span><span style="font-family:'Times New Roman'; font-size:12pt">eg</span><span style="font-family:'Times New Roman'; font-size:12pt"> </span><span style="font-family:'Times New Roman'; font-size:12pt">expensive</span><span style="font-family:'Times New Roman'; font-size:12pt"> A&amp;E attendances and unplanned </span><span style="font-family:'Times New Roman'; font-size:12pt">hospital </span><span style="font-family:'Times New Roman'; font-size:12pt">admission</span><span style="font-family:'Times New Roman'; font-size:12pt">s</span><span style="font-family:'Times New Roman'; font-size:12pt"> are </span><span style="font-family:'Times New Roman'; font-size:12pt">welcome but</span><span style="font-family:'Times New Roman'; font-size:12pt"> poor provision and </span><span style="font-family:'Times New Roman'; font-size:12pt">local </span><span style="font-family:'Times New Roman'; font-size:12pt">service restrictions </span><span style="font-family:'Times New Roman'; font-size:12pt">due to</span><span style="font-family:'Times New Roman'; font-size:12pt"> short-term budget thinking will </span><span style="font-family:'Times New Roman'; font-size:12pt">significantly restrict </span><span style="font-family:'Times New Roman'; font-size:12pt">the success of such </span><span style="font-family:'Times New Roman'; font-size:12pt">measures. </span></li></ol><p style="font-size:12pt; line-height:115%; margin:0pt 13.05pt 0pt 36pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; margin:0pt 13.05pt 0pt 32pt; padding-left:4pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">Indeed, a report published by the Public Accounts Committee in March 2013 revealed concerns that the NHS is seeking </span><span style="font-family:'Times New Roman'; font-size:12pt">‘</span><span style="font-family:'Times New Roman'; font-size:12pt">to make savings by rationing patients’ access to certain treatments</span><span style="font-family:'Times New Roman'; font-size:12pt">’</span><span style="font-family:'Times New Roman'; font-size:12pt">.</span></li></ol><p style="margin:0pt 13.05pt 0pt 0pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; margin:0pt 13.05pt 0pt 31.85pt; padding-left:3.85pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">This submission, whilst recognising </span><span style="font-family:'Times New Roman'; font-size:12pt">the need to make financial efficiencies in the NHS, </span><span style="font-family:'Times New Roman'; font-size:12pt">advocates that </span><span style="font-family:'Times New Roman'; font-size:12pt">formulary and prescribing decisions </span><span style="font-family:'Times New Roman'; font-size:12pt">be</span><span style="font-family:'Times New Roman'; font-size:12pt"> based on treatment optimisation and </span><span style="font-family:'Times New Roman'; font-size:12pt">that</span><span style="font-family:'Times New Roman'; font-size:12pt"> decision makers take into considerati</span><span style="font-family:'Times New Roman'; font-size:12pt">on </span><span style="font-family:'Times New Roman'; font-size:12pt">the value </span><span style="font-family:'Times New Roman'; font-size:12pt">medical technology </span><span style="font-family:'Times New Roman'; font-size:12pt">make</span><span style="font-family:'Times New Roman'; font-size:12pt">s</span><span style="font-family:'Times New Roman'; font-size:12pt"> to facilitating</span><span style="font-family:'Times New Roman'; font-size:12pt"> self</span><span style="font-family:'Times New Roman'; font-size:12pt">-management</span><span style="font-family:'Times New Roman'; font-size:12pt">,</span><span style="font-family:'Times New Roman'; font-size:12pt"> </span><span style="font-family:'Times New Roman'; font-size:12pt">an </span><span style="font-family:'Times New Roman'; font-size:12pt">integral</span><span style="font-family:'Times New Roman'; font-size:12pt"> part of the solution.</span></li></ol><p style="margin:0pt 13.05pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 13.05pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Diabetes</span></p><p style="margin:0pt 13.05pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; margin:0pt 13.05pt 0pt 32pt; padding-left:4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">Roche Diagnostics UK</span><span style="font-family:'Times New Roman'; font-size:12pt"> welcome</span><span style="font-family:'Times New Roman'; font-size:12pt">s</span><span style="font-family:'Times New Roman'; font-size:12pt"> Baroness Young of Old Scone’s oral evidence to the inquiry and the focus on diabetes. </span><span style="font-family:'Times New Roman'; font-size:12pt">According to Diabetes UK, between 2006 and 2011, the number of people diagnosed with diabetes </span><span style="font-family:'Times New Roman'; font-size:12pt">in England increased by 25 per cent, f</span><span style="font-family:'Times New Roman'; font-size:12pt">rom 1.9 million to 2.5 million. </span><span style="font-family:'Times New Roman'; font-size:12pt">Diabetes is now the biggest single cause of amputation, stroke, bli</span><span style="font-family:'Times New Roman'; font-size:12pt">ndness</span><span style="font-family:'Times New Roman'; font-size:12pt"> and end-stage kidney failure. The reality of any of those devastating outcomes for patients demonstrates the NHS</span><span style="font-family:'Times New Roman'; font-size:12pt"> is not able to plan for or manage the realities of long-term diabetes outcomes, including the multiple conditions a person with diabetes is likely to develop in the later stages of having the condition.</span><a name="_ftnref1"></a><a href="#_ftn1">[1]</a><span style="font-family:'Times New Roman'; font-size:12pt"> </span></li></ol><p style="margin:0pt 13.05pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; margin:0pt 13.05pt 0pt 32pt; padding-left:4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">Considering current diabetes spend accounts for a</span><span style="font-family:'Times New Roman'; font-size:12pt">round 10 per cent of the NHS budget, roughly £10 billion per year in England, the NHS needs to ensure that everything is being done to encourage patients to maintain good diabetes control</span><span style="font-family:'Times New Roman'; font-size:12pt">, including the self-monitoring of blood glucose</span><span style="font-family:'Times New Roman'; font-size:12pt">.</span><span style="font-family:'Times New Roman'; font-size:12pt"> However, the signif</span><span style="font-family:'Times New Roman'; font-size:12pt">icance of self-management and the integral role medical technology plays in managing long-term conditions has been </span><span style="font-family:'Times New Roman'; font-size:12pt">largely absent</span><span style="font-family:'Times New Roman'; font-size:12pt"> from the inquiry. </span></li></ol><p style="font-size:12pt; line-height:115%; margin:0pt 13.05pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ol start="7" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; margin:0pt 13.05pt 0pt 32pt; padding-left:4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">Over the last two decades it has been firmly established that tight glycaemic control is associated with a</span><span style="font-family:'Times New Roman'; font-size:12pt"> signif</span><span style="font-family:'Times New Roman'; font-size:12pt">icant reduction in serious long-</span><span style="font-family:'Times New Roman'; font-size:12pt">term diabetes related complications. Self-monitoring of blood glucose (SMBG) is an effective tool in the self-management of glucose levels in people with Type 1 diabetes and people with Type 2 diabetes using insulin t</span><span style="font-family:'Times New Roman'; font-size:12pt">herapy. It helps people with diabetes using insulin achieve tight </span><span style="font-family:'Times New Roman'; font-size:12pt">glycaemic control and to identify low blood glucose levels before the development of severe hypoglycaemia</span><span style="font-family:'Times New Roman'; font-size:12pt"> and the need for medical attention</span><span style="font-family:'Times New Roman'; font-size:12pt">.</span><a name="_ftnref2"></a><a href="#_ftn2">[2]</a></li></ol><p style="margin:0pt 13.05pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:12pt 13.05pt 0pt 0pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Self-monitoring of blood glucose (SMBG) </span></p><p style="margin:0pt 13.05pt 0pt 0pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">&#xa0;</span></p><ol start="8" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; margin:0pt 13.05pt 0pt 31.85pt; padding-left:3.85pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">Monitoring blood glucose is a very important part of managing diabetes. Regularly testing blood glucose helps measure the effectiveness of a patient’s dietary planning, exercise and medication, with good control helping reduce longer-term complications. In</span><span style="font-family:'Times New Roman'; font-size:12pt"> order to self-test blood glucose, a patient needs a blood glucose meter, a test strip and a finger pricker. </span></li></ol><p style="margin:0pt 13.05pt 0pt 35.7pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ol start="9" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; margin:0pt 13.05pt 0pt 31.85pt; padding-left:3.85pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">In England, the blood glucose meter and finger pricker is provided free through the NHS </span><span style="font-family:'Times New Roman'; font-size:12pt">by</span><span style="font-family:'Times New Roman'; font-size:12pt"> a</span><span style="font-family:'Times New Roman'; font-size:12pt"> healthcare professional. </span><span style="font-family:'Times New Roman'; font-size:12pt">Test strips are then provid</span><span style="font-family:'Times New Roman'; font-size:12pt">ed on prescription, with the number of tests allocated based on the frequency of testing required </span><span style="font-family:'Times New Roman'; font-size:12pt">eg</span><span style="font-family:'Times New Roman'; font-size:12pt"> depending on the type of diabetes, level of physical activity and </span><span style="font-family:'Times New Roman'; font-size:12pt">driving frequency</span><span style="font-family:'Times New Roman'; font-size:12pt">.</span><span style="font-family:'Times New Roman'; font-size:12pt"> </span></li></ol><p style="font-size:12pt; line-height:115%; margin:0pt 13.05pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ol start="10" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; margin:0pt 13.05pt 0pt 35.7pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">The annual cost of blood glucose test strips for the NHS stands at £</span><span style="font-family:'Times New Roman'; font-size:12pt">150 million, representing 1.1% of the total spend on diabetes and its complications.</span><a name="_ftnref3"></a><a href="#_ftn3">[3]</a></li></ol><p style="font-size:12pt; line-height:115%; margin:0pt 13.05pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ol start="11" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; margin:0pt 13.05pt 0pt 35.7pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">Unfortunately, short-term financial savings by local decision makers are, in an increasing number of incidences, threatening self-management</span><span style="font-family:'Times New Roman'; font-size:12pt">. </span><span style="font-family:'Times New Roman'; font-size:12pt">For example, restrictions </span><span style="font-family:'Times New Roman'; font-size:12pt">around access to blood glucose test strips or inconsistent formulary processes/decisions surrounding the type of blood glucose meter made available to patients.</span></li></ol><p style="margin:0pt 13.05pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:12pt 13.05pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Diabetes </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">self-monitoring</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold"> restriction</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">s</span></p><p style="margin:0pt 13.05pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ol start="12" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; margin:0pt 13.05pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">There are </span><span style="font-family:'Times New Roman'; font-size:12pt">2.5 million people in England living</span><span style="font-family:'Times New Roman'; font-size:12pt"> </span><span style="font-family:'Times New Roman'; font-size:12pt">with </span><span style="font-family:'Times New Roman'; font-size:12pt">diabetes, including 250,000 with Type 1 diabetes. Their lives, along with a small percentage of type 2 patients, </span><span style="font-family:'Times New Roman'; font-size:12pt">depend on insulin injection or pump treatment, which requires them to regularly carry out self-blood glucose measurements (SBGM), normally seve</span><span style="font-family:'Times New Roman'; font-size:12pt">ral tests a day eg upon waking, before/after eating and before bed.</span></li></ol><p style="margin:0pt 13.05pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ol start="13" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; margin:0pt 13.05pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">However, people with Type 1 diabetes are increasingly being restricted access to test strips.</span><span style="font-family:'Times New Roman'; font-size:12pt"> </span><span style="font-family:'Times New Roman'; font-size:12pt">In a letter circulated to General Practitioners, Hospital Doctors, Community Pharmacists and </span><span style="font-family:'Times New Roman'; font-size:12pt">PCT Chief Executives in February 2013, the National Clinical Director for Diabetes reaffirmed the importance of  testing, stating it is ‘essential that people with Type 1 diabetes are prescribed sufficient SBGM testing strips for their clinical needs (as o</span><span style="font-family:'Times New Roman'; font-size:12pt">utlined in NICE guidance CG15, TA 60). This enables people with diabetes to self-manage, recognising the symptoms of </span><span style="font-family:'Times New Roman'; font-size:12pt">d</span><span style="font-family:'Times New Roman'; font-size:12pt">iabetic ketoacidosis, encouraging them to take early action and seek help, especially if it involves</span><span style="font-family:'Times New Roman'; font-size:12pt"> driving.</span></li></ol><p style="margin:0pt 13.05pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ol start="14" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; margin:0pt 13.05pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">The letter also clarified t</span><span style="font-family:'Times New Roman'; font-size:12pt">hat “While testing strips dispensed in primary care may appear to have a premium cost, the wider costs to the patient’s quality of life, their safety and ability to work and to the NHS of complications of uncontrolled diabetes far outweigh </span><span style="font-family:'Times New Roman'; font-size:12pt">these costs, inc</span><span style="font-family:'Times New Roman'; font-size:12pt">luding the cost of repeated unplanned A&amp;E admissions. Further costs for the strips in most cases also include provision of educational material, meters, and helplines for patients by the manufacturer.”</span><a name="_ftnref4"></a><a href="#_ftn4">[4]</a><span style="font-family:'Times New Roman'; font-size:12pt"> </span></li></ol><p style="font-size:12pt; line-height:115%; margin:0pt 13.05pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ol start="15" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; margin:0pt 13.05pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">Despite that letter, a </span><span style="font-family:'Times New Roman'; font-size:12pt">survey carried out </span><span style="font-family:'Times New Roman'; font-size:12pt">by DUK </span><span style="font-family:'Times New Roman'; font-size:12pt">in March-April </span><span style="font-family:'Times New Roman'; font-size:12pt">2013 </span><span style="font-family:'Times New Roman'; font-size:12pt">confirms strip restrictions continue to affect patients with</span><span style="font-family:'Times New Roman'; font-size:12pt"> both T</span><span style="font-family:'Times New Roman'; font-size:12pt">ype</span><span style="font-family:'Times New Roman'; font-size:12pt"> 1 and T</span><span style="font-family:'Times New Roman'; font-size:12pt">ype </span><span style="font-family:'Times New Roman'; font-size:12pt">2</span><span style="font-family:'Times New Roman'; font-size:12pt"> diabetes.</span><span style="font-family:'Times New Roman'; font-size:12pt"> From a </span><span style="font-family:'Times New Roman'; font-size:12pt">sample</span><span style="font-family:'Times New Roman'; font-size:12pt"> of </span><span style="font-family:'Times New Roman'; font-size:12pt">2,203</span><span style="font-family:'Times New Roman'; font-size:12pt"> patients and ca</span><span style="font-family:'Times New Roman'; font-size:12pt">re</span><span style="font-family:'Times New Roman'; font-size:12pt">r</span><span style="font-family:'Times New Roman'; font-size:12pt">s,</span><span style="font-family:'Times New Roman'; font-size:12pt"> </span><span style="font-family:'Times New Roman'; font-size:12pt">39% had either been refused a prescription of blood glucose test strips or had their prescription </span><span style="font-family:'Times New Roman'; font-size:12pt">restricted</span><span style="font-family:'Times New Roman'; font-size:12pt">. O</span><span style="font-family:'Times New Roman'; font-size:12pt">f those</span><span style="font-family:'Times New Roman'; font-size:12pt">,</span><span style="font-family:'Times New Roman'; font-size:12pt"> 55% had test strips restricted within the last year </span><span style="font-family:'Times New Roman'; font-size:12pt">and</span><span style="font-family:'Times New Roman'; font-size:12pt"> 33% </span><span style="font-family:'Times New Roman'; font-size:12pt">experienced</span><span style="font-family:'Times New Roman'; font-size:12pt"> a prescription being refused or re</span><span style="font-family:'Times New Roman'; font-size:12pt">stricted in the last six months</span><span style="font-family:'Times New Roman'; font-size:12pt">.</span><a name="_ftnref5"></a><a href="#_ftn5">[5]</a><span style="font-family:'Times New Roman'; font-size:12pt"> </span></li></ol><p style="margin:0pt 13.05pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ol start="16" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; line-height:12.05pt; margin:0pt 13.05pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">In the past</span><span style="font-family:'Times New Roman'; font-size:12pt">,</span><span style="font-family:'Times New Roman'; font-size:12pt"> </span><span style="font-family:'Times New Roman'; font-size:12pt">blood glucose testing </span><span style="font-family:'Times New Roman'; font-size:12pt">restriction</span><span style="font-family:'Times New Roman'; font-size:12pt">s</span><span style="font-family:'Times New Roman'; font-size:12pt"> mainly focused</span><span style="font-family:'Times New Roman'; font-size:12pt"> on people with Type 2 diabetes. H</span><span style="font-family:'Times New Roman'; font-size:12pt">owever </span><span style="font-family:'Times New Roman'; font-size:12pt">the DUK survey highlighted that over half of the respondents </span><span style="font-family:'Times New Roman'; font-size:12pt">had Type 1 diabetes (or were carers) of people with Type</span><span style="font-family:'Times New Roman'; font-size:12pt"> 1.</span><span style="font-family:'Times New Roman'; font-size:12pt"> This is largely unprecedented and the impact on individuals is considerable, </span><span style="font-family:'Times New Roman'; font-size:12pt">given the cost of</span><span style="font-family:'Times New Roman'; font-size:12pt"> poor </span><span style="font-family:'Times New Roman'; font-size:12pt">glycaemic control. </span></li></ol><p style="font-size:12pt; line-height:115%; margin:0pt 0pt 10pt 36pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="font-size:12pt; line-height:115%; margin:0pt 13.05pt 10pt 0pt"><a name="_GoBack"></a><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Access to innovative blood glucose testing</span></p><ol start="17" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; margin:0pt 13.05pt 0pt 36pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">Long-term conditions account for: 50 per cent of GP appointments, 70 per cent of bed days and 70 per cent of health and care budgets. Reducing their cost burden cannot be achieved </span><span style="font-family:'Times New Roman'; font-size:12pt">through treatment restriction as this will lead to costly complications. With an annual cost of £10 billion, there is plenty of money spent on diabetes care but it is spent in the wrong places. The NHS’s focus needs to shift towards service redesign, the d</span><span style="font-family:'Times New Roman'; font-size:12pt">ecommissioning of ineffective services and the increased adoption of self-management</span><span style="font-family:'Times New Roman'; font-size:12pt"> technology</span><span style="font-family:'Times New Roman'; font-size:12pt"> so patients can take a more active role in managing their conditions.  </span></li></ol><p style="margin:0pt 13.05pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ol start="18" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; margin:0pt 13.05pt 0pt 36pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">Technology for accurate and effective self-monitoring and management is available. Remo</span><span style="font-family:'Times New Roman'; font-size:12pt">te and other forms of diagnostic monitoring are being used to support self and directed management approaches. While these services are already is use within the NHS, poor commissioning and a failure to decommission poor-value services are limiting their u</span><span style="font-family:'Times New Roman'; font-size:12pt">ptake.</span></li></ol><p style="font-size:12pt; line-height:115%; margin:0pt 13.05pt 10pt 0pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">&#xa0;</span></p><p style="font-size:12pt; line-height:115%; margin:0pt 13.05pt 10pt 0pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Conclusion</span></p><ol start="19" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; line-height:13.8pt; margin:0pt 13.05pt 13.75pt 36pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">It is essential that people with </span><span style="font-family:'Times New Roman'; font-size:12pt">Type 1 </span><span style="font-family:'Times New Roman'; font-size:12pt">diabetes are prescribed sufficient SBGM testing strips for their clinical needs. Provision of these strips and their use needs to be in context of a wider on-going patient education programme (as outlined in NICE guidance CG15, TA 60, and the NICE QIPP exa</span><span style="font-family:'Times New Roman'; font-size:12pt">mple Dietary Adjustment for Normal Eating or DAFNE course). </span></li><li style="font-family:'Times New Roman'; font-size:12pt; line-height:12.05pt; margin:0pt 13.05pt 0pt 36pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">Self-monitoring of blood glucose levels should be part of an integrated package of care as defined by national guidelines and decisions about blood glucose monitoring should be made in consultati</span><span style="font-family:'Times New Roman'; font-size:12pt">on between the person with diabetes and their health care professional. </span></li></ol><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ol start="21" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; line-height:12.05pt; margin:0pt 13.05pt 0pt 36pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">Greater provision of</span><span style="font-family:'Times New Roman'; font-size:12pt"> education, which includes self-</span><span style="font-family:'Times New Roman'; font-size:12pt">monitoring of blood glucose levels, should be provided to people with diabetes showing </span><span style="font-family:'Times New Roman'; font-size:12pt">patient</span><span style="font-family:'Times New Roman'; font-size:12pt"> how to interpret results to adapt </span><span style="font-family:'Times New Roman'; font-size:12pt">diet, lifestyle and medication to achieve optimal outcome in order that </span><span style="font-family:'Times New Roman'; font-size:12pt">they can use self-</span><span style="font-family:'Times New Roman'; font-size:12pt">monitoring effectively. </span></li></ol><p style="margin:0pt 13.05pt 0pt 0pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ol start="22" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; line-height:12.05pt; margin:0pt 13.05pt 10pt 36pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">Healthcare professionals should not carry out arbitrary withdrawal of SMBG in those individuals who do not take insulin but clearly benefit </span><span style="font-family:'Times New Roman'; font-size:12pt">from measuring their glucose. </span><span style="font-family:'Times New Roman'; font-size:12pt">Blanket policies restricting the number of test strips or meter choices should be removed and focus placed on supporting clinicians on how to approach individual assessment and review to reduce waste and meet individual needs.</span><span style="font-family:'Times New Roman'; font-size:12pt"> </span></li></ol><p style="margin:0pt 13.05pt 0pt 0pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="font-size:12pt; line-height:115%; margin:0pt 13.05pt 10pt 0pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">About Roche Diagnostics UK </span></p><ol start="23" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; margin:0pt 13.05pt 0pt 36pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">Roche Diagnostics is the world’s largest in vitro diagnostics company, supplying high quality products and services which are used to diagnose and monitor medical conditions and facilitate medical research. From small devices</span><span style="font-family:'Times New Roman'; font-size:12pt"> used directly by patients or healthcare professionals, to large diagnostic instruments found in hospital laboratories, Roche has a track record of developing new and innovative devices.</span></li></ol><p style="margin:0pt 13.05pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ol start="24" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; margin:0pt 13.05pt 0pt 36pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">Roche has pioneered the development of hand held systems, </span><span style="font-family:'Times New Roman'; font-size:12pt">empowering patients with diabetes and those receiving anticoagulation therapy, to monitor their own long-term conditions easily and accurately.</span></li></ol><p style="margin:0pt 13.05pt 0pt 0pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ol start="25" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:12pt; margin:0pt 13.05pt 0pt 36pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">Roche Diabetes Care’s Accu-Chek® brand is the world leader in diabetes care, with a diverse portfolio of produ</span><span style="font-family:'Times New Roman'; font-size:12pt">cts designed to help people with diabetes live healthy, productive lives and to make managing diabetes easier.</span></li></ol><p style="margin:0pt 13.05pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="font-size:12pt; line-height:115%; margin:0pt 13.05pt 10pt 0pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic">November 2013</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p></div><hr style="width:33%; height:1px; text-align:left" /><p style="margin:0pt"><a name="_ftn1"></a><a href="#_ftnref1">[1]</a><span style="font-family:Calibri; font-size:10pt"> State of the Nation 2012: England, Diabetes UK</span></p><p style="margin:0pt"><a name="_ftn2"></a><a href="#_ftnref2">[2]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:Calibri; font-size:10pt">Self-monitoring of </span><span style="font-family:Calibri; font-size:10pt">blood glucose levels f</span><span style="font-family:Calibri; font-size:10pt">or adults with Type 2 diabetes, April 2013, Diabetes UK</span></p><p style="margin:0pt"><a name="_ftn3"></a><a href="#_ftnref3">[3]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:Calibri; font-size:10pt">Cardiovascular - type 2 diabetes. Data focused commentary: Type 2 diabetes: Self-monitoring blood glucose. Nat</span><span style="font-family:Calibri; font-size:10pt">ional Prescribing Centre (2012)</span></p><p style="margin:0pt"><a name="_ftn4"></a><a href="#_ftnref4">[4]</a><span style="font-family:Calibri; font-size:10pt"> </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/156336/Safe-care-of-people-with-type-1-diabetes.pdf.pdf"><span style="color:#0000ff; font-family:Calibri; font-size:10pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/156336/Safe-care-of-people-with-type-1-diabetes.pdf.pdf</span></a><span style="font-family:Calibri; font-size:10pt"> (accessed 01</span><span style="font-family:Calibri; font-size:10pt"> November</span><span style="font-family:Calibri; font-size:10pt"> 2013)</span></p><p style="margin:0pt"><a name="_ftn5"></a><a href="#_ftnref5">[5]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:Calibri; font-size:10pt">ACCESS TO TEST STRIPS: A POSTCODE LOTTERY? </span><span style="font-family:Calibri; font-size:10pt">Self-monitoring</span><span style="font-family:Calibri; font-size:10pt"> of blood glucose by people with Type 1 and Type 2 diabetes, August 2013, Diabetes UK</span></p></body></html>